IPA RNA-Seq Customer Satisfaction
How satisfied are you with the value for identifying biologically relevant isoforms from RNA seq data using IPA?
Extremely satisfied: 14%
Very satisfied: 34%
Satisfied: 49%
Dissatisfied: 3%
Rate the following Ingenuity Variant Analysis capabilities in terms of how differentiated they are compared to other data analysis solutions you have used.
5 (Strongly differentiated)
4 (Very differentiated)
3 (Differentiated)
2 (Somewhat differentiated)
1 (Not differentiated)
| Accessible / Easy to use |
|
| Sharing with colleagues/peers |
|
| Fast |
|
| Accurate evidence |
|
| Secure |
|
What types of challenges did deploying Ingenuity Variant Analysis solve for your laboratory or organization?
| Faster and easier identification of causal variants |
|
|
| Improved access to biological content including primary sources |
|
|
| Reduced the need for developing own informatics pipeline |
|
|
| Enabled me to do my study on my own without the need for specialized bioinformatics skills |
|
|
| Eliminated the need for creating and maintaining own up-to-date database of biomedical literature |
|
|
| Enabled me to support more studies by providing a self-service tool for my colleagues and collaborators |
|
|
| Improved sharing and collaboration capabilities |
|
|
| Reduced IT infrastructure costs |
|
What were the top drivers for selecting Ingenuity Variant Analysis?
| Access to rich biological content in Ingenuity Knowledge Base plus additional sources of variant level content |
|
|
| Reduced time to identify variants worth following up on |
|
|
| Identify high impact, most compelling variants to follow up on |
|
|
| User friendly interface and no bioinformatics experience needed |
|
|
| Easy to collaborate and share with colleagues and peers |
|
|
| Secure web application that is HIPAA and Safe Harbor compliant |
|
|
| Scalable from small to large studies |
|
|
| Increased trust in the insights received from my experiment |
|